A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Non-Small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; T lymphocyte cell therapies (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 08 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 26 Sep 2018 Results (n=14) presented at the 19th World Conference on Lung Cancer.
- 11 Oct 2017 Status changed from not yet recruiting to recruiting.